CU23892B1 - Composición farmacéutica microencapsulada de ciclosporina a - Google Patents

Composición farmacéutica microencapsulada de ciclosporina a

Info

Publication number
CU23892B1
CU23892B1 CUP2007000274A CU20070274A CU23892B1 CU 23892 B1 CU23892 B1 CU 23892B1 CU P2007000274 A CUP2007000274 A CU P2007000274A CU 20070274 A CU20070274 A CU 20070274A CU 23892 B1 CU23892 B1 CU 23892B1
Authority
CU
Cuba
Prior art keywords
cyclosporine
pharmaceutical composition
water
microencapsulated
microencapsulated pharmaceutical
Prior art date
Application number
CUP2007000274A
Other languages
English (en)
Other versions
CU20070274A6 (es
Inventor
Hernández Orestes López
Carril Martha Gómez
Izquierdo Suslebys Salomón
Original Assignee
Ct De Investigación Y Desarrollo De Medicamentos Cidem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40717312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU23892(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ct De Investigación Y Desarrollo De Medicamentos Cidem filed Critical Ct De Investigación Y Desarrollo De Medicamentos Cidem
Priority to CUP2007000274A priority Critical patent/CU23892B1/es
Priority to ARP080105294A priority patent/AR069578A1/es
Priority to PCT/CU2008/000011 priority patent/WO2009071034A1/es
Publication of CU20070274A6 publication Critical patent/CU20070274A6/es
Publication of CU23892B1 publication Critical patent/CU23892B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composición farmacéutica de ciclosporina A microencapsulada mediante secado por aspersión, modificando su solubilidad en agua y en fluido gastrointestinal con ayuda de un tensoactivo hidrofílico y uso de una mezcla de polímeros como Dextrana y polietilenglicol 4000 para aumentar su estabilidad en agua contribuyendo a mantenerla estable en agua por más de 24 horas, lo que coadyuva amejorar la absorción de la misma.
CUP2007000274A 2007-12-07 2007-12-07 Composición farmacéutica microencapsulada de ciclosporina a CU23892B1 (es)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CUP2007000274A CU23892B1 (es) 2007-12-07 2007-12-07 Composición farmacéutica microencapsulada de ciclosporina a
ARP080105294A AR069578A1 (es) 2007-12-07 2008-12-04 Composicion farmaceutica de ciclosporina a y procedimiento para modificar su solubilidad y estabilidad
PCT/CU2008/000011 WO2009071034A1 (es) 2007-12-07 2008-12-05 Composicion farmaceútica de ciclosporina a y procedimiento para modificar su solubilidad y estabilidad

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CUP2007000274A CU23892B1 (es) 2007-12-07 2007-12-07 Composición farmacéutica microencapsulada de ciclosporina a

Publications (2)

Publication Number Publication Date
CU20070274A6 CU20070274A6 (es) 2011-10-31
CU23892B1 true CU23892B1 (es) 2013-04-19

Family

ID=40717312

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2007000274A CU23892B1 (es) 2007-12-07 2007-12-07 Composición farmacéutica microencapsulada de ciclosporina a

Country Status (3)

Country Link
AR (1) AR069578A1 (es)
CU (1) CU23892B1 (es)
WO (1) WO2009071034A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008785D0 (en) * 2000-04-10 2000-05-31 Novartis Ag Organic compounds
WO2004012714A1 (en) * 2002-08-05 2004-02-12 Dsm Ip Assets B.V. Oral dosage forms of water insoluble drugs and methods of making the same
US20070196396A1 (en) * 2004-02-11 2007-08-23 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability

Also Published As

Publication number Publication date
CU20070274A6 (es) 2011-10-31
AR069578A1 (es) 2010-02-03
WO2009071034A1 (es) 2009-06-11

Similar Documents

Publication Publication Date Title
ECSP109852A (es) Uso de homo y copolímeros para la estabilización de formulaciones de principios activos
UY29005A1 (es) Composiciones plaguicidas líquidas.-
GT201000047A (es) Mejoras en compuestos organicos o relacionadas con los mismos
UY30319A1 (es) Formulaciones de inhibidores de dpp iv
BRPI0810863A2 (pt) Uso de hidrolisados de proteína para estabilizar formulações de detergente de metaloprotease.
BRPI0810552A2 (pt) Composição de substância ativa, processos para preparar uma composição de substância ativa, e para preparar sementes contenda substância ativa, uso da composição de substância ativa, sementes, e, composição aquosa.
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
EA200701661A1 (ru) Композиция активного вещества
BRPI0813341A2 (pt) " uso de compostos, composições curáveis, e, uso de composições curáveis ".
BRPI0922435A2 (pt) "composto de tiazolopiridina moduladores de sirtuina, composição farmacêutica compreendendo o mesmo e seu uso."
AR053737A1 (es) Formulacion pediatrica de topiramato
BRPI0908097A2 (pt) uso de pelo menos um composto, peptídeo, e, formulação farmacêutica.
CL2007002377A1 (es) Compuestos derivados de quinazolina; procedimiento de preparacion; composicion farmaceutica; y su uso como anticancerigeno.
UY32659A (es) Pirazinilpirazoles
CL2007002971A1 (es) Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras.
CO6280573A2 (es) Concentrados en suspension basados en aceite
CL2012001310A1 (es) Composicion que comprende un oligopeptido ciclo-(arg-gly-asp-dphe-nmeval) que tiene una solubilidad en agua a 20ºc de entre 1 mg/ml y 20 mg/ml y con uno o varios compuestos lipofilicos y/o anfifílicos; proceso para preparar dicha composicion.
AR110174A2 (es) Agentes endoparasiticidas y procedimiento de preparación
CR9786A (es) Compuestos de bencimidazol-tiofeno
BRPI0604330A (pt) composições compreendendo emulsificantes poliméricos e métodos para seu uso
CL2007002970A1 (es) Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras.
CL2007003643A1 (es) Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas.
CL2007002862A1 (es) Uso del factor de crecimiento epidermico (egf) para tratar neuropatia sensitivo-motora, dolorosa y manifestaciones de neuritis isquemicas; composicion farmaceutica que comprende egf; y uso de la composicion antes dicha.
BRPI0911772A2 (pt) composto, composição farmacêutica, e, uso do composto.
CL2013002339A1 (es) Composicion adhesiva estable, que incluye un disolvente sin urea, y harina de soya en agua, la composicion tiene un ph inferior a 5, y el disolvente sin urea se selecciona entre glicerol, glicol etileno, propilenglicol, neopentil y combinacion polimericas de los mismos.

Legal Events

Date Code Title Description
FG Grant of patent